Teva Pharmaceutical Industries Limited (TEVA) : During the past 4 weeks, traders have been relatively bearish on Teva Pharmaceutical Industries Limited (TEVA), hence the stock is down -3.44% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.07% relative to the S&P 500. The 4-week change in the price of the stock is -3.64% and the stock has fallen -2.72% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.92% and the fifty day Moving Average is 1.61%. Teva Pharmaceutical Industries Limited is up 0.43% in the last three month period. Year-to-Date the stock performance stands at -19.95%.
Teva Pharmaceutical Industries Limited (TEVA) stock is expected to deviate a maximum of $10.59 from the average target price of $72.59 for the short term period. 15 Street Experts have initiated coverage on the stock with the most promising target being $100 and the most muted being $57.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): stock turned positive on Friday. Though the stock opened at $51.35, the bulls momentum made the stock top out at $51.977 level for the day. The stock recorded a low of $51.14 and closed the trading day at $51.55, in the green by 0.68%. The total traded volume for the day was 5,395,826. The stock had closed at $51.2 in the previous days trading.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.